Medical Marijuana Market Size, Share, and Growth Forecast for 2025 - 2032

The global medical marijuana market size is anticipated to reach a value of US$ 33.1 Bn in 2025 and is set to witness a CAGR of 14.0% from 2025 to 2032. The market will likely attain a value of US$ 83.1 Bn in 2032.

In homes, clinics, and research labs, the stigma surrounding medical marijuana is slowly dissipating, replaced by a surging recognition of its therapeutic potential. Patients who had previously accepted using conventional medications to treat crippling disorders and persistent pain are starting to learn about its benefits.

This realization is spurring a wave of investment and innovation, transforming the global medical marijuana market into a dynamic and quickly changing environment. Businesses are coming up to satisfy the rising need for secure and efficient marijuana-based therapies, from North American farms to European pharmaceutical laboratories. A new era in healthcare, where medical marijuana will play a key role in evolving patient care and wellbeing for millions, is projected to begin as governments worldwide update their laws.

Key Highlights of the Medical Marijuana Industry

• North America is estimated to hold a share of 39% in 2025 as government bodies in the U.S. and Canada strive to legalize cannabis cultivation and research activities.
• The extract form segment by product will likely generate 65% share in 2025 due to high effectiveness of products like oils, edibles, and tinctures.
• Based on distribution channel, retail pharmacies are likely to hold 77% share in 2025 due to availability of OTC products in certain countries.
• By indication, pain management is anticipated to account for 48% share in 2025 backed by rising use among patients due to marijuana’s anti-inflammatory effect.
• Ability of medical marijuana to act as an immediate bronchodilator is projected to help manage symptoms of asthma like wheezing and coughing.
• Emergence of social groups that help patients recognize the benefits of medical marijuana for treating chronic pain and seizures is set to create opportunities.

Cross-border Trade Opportunities Grew in Historical Period as Countries Approved Therapeutic Use of Marijuana

In the historical period from 2019 to 2024, the global medical marijuana industry witnessed a CAGR of 12.8%. It was augmented by rising acceptance among patients and healthcare professionals, changing regulations, and innovations in research.

During the historical period, several countries made notable progress in creating strong legal frameworks for the use of marijuana for medical purposes, which increased access and sparked a boom in production and cultivation. As more countries approved the drug's therapeutic use, the global market started to change, creating a more competitive space and higher chances for cross-border trade.

A significant milestone occurred in December 2024, when Tikun Olam Europe became the first medical cannabis company in Greece by setting new standards. It completed the country’s first export of finished medical cannabis products. This marked the company’s official entry into international markets, with Switzerland as the destination. The export was carried out in collaboration with the Swiss pharmaceutical company MediCrops AG.

Rising Demand for Customized Medical Marijuana Products to Compel Companies to Extend Product Lines

From 2025 to 2032, the medical marijuana industry is likely to showcase a CAGR of 14.0%. It is anticipated to rise steadily as regulatory frameworks evolve worldwide. Companies will likely concentrate on extending their product lines to meet the demands of individual patients as the need for a variety of medical marijuana products rises.

The products are set to include formulations and balanced extracts that give customized medicinal effects. Market leaders and newcomers are projected to compete more fiercely as they try to make their mark in an increasingly profitable environment.

A key example of this trend emerged in February 2025, when Tilray Medical, a division of Tilray Brands, announced an expansion of its medical cannabis extract portfolio in Germany. The company introduced two new product offerings to meet the high demand for balanced medical cannabis extracts. With this expansion, Tilray reaffirmed its position as the leading provider of medical marijuana extracts in Germany.

Growth Drivers

Ongoing Research on Medical Marijuana Aims to Enhance Quality of Life for Cancer Patients

Marijuana is being researched for its potential benefits in managing some of the adverse effects of cancer and its therapy for cancer patients. However, under certain circumstances, forms, and dosages, the product can be dangerous.

Marijuana cannot stop or inhibit the growth of cancer cells, according to studies. Guidelines for oncologists treating adults with cancer have been developed by experts at the American Society for Clinical Oncology (ASCO). According to the recommendation, unless cannabis-based products are being researched in a clinical trial, these should not be utilized as a cancer treatment. The approved medicinal applications of marijuana listed by the U.S. FDA for issues that cancer patients frequently experience include sleep problems, pain, anxiety and stress, loss of appetite, and nausea and vomiting. While research work is still underway, healthcare professionals are set to focus on coming up with innovative marijuana-based products for cancer patients to help them cope with painful side effects.

Social Stigma and Lack of In-depth Clinical Evidence May Hamper the Market

The medical marijuana industry often encounters opposition from different communities and is suppressed by the public due to its social stigma. According to their primary business, medical marijuana is processed to be useful in terms of medicine. Regarding its therapeutic benefits, manufacturers do believe that consumer perception is important in this unclear business model.

The lack of adequate yet compelling clinical evidence about the effectiveness of medicinal marijuana for several conditions is one of the key challenges faced by its use worldwide. Even if firsthand accounts indicate that there are benefits, thorough research involving various patients is necessary before a physician recommends such treatments. In most healthcare systems, the lack of such scientific assessments discourages the use of medical marijuana and causes patients to have low confidence.

Mental Health Management to be a Flourishing Segment for Key Companies

The medical marijuana industry is projected to see opportunities in the mental health management segment. Due to increasing awareness of its ability to treat anxiety, depression, PTSD, and insomnia, its use is anticipated to rise through 2032. For example,

• After switching to medical marijuana, almost two-thirds of patients with anxiety disorders reported using fewer antianxiety drugs.

Adoption of the marijuana treatment is also influenced by increased knowledge of mental health concerns. Medical marijuana is transforming the psychiatric field and creating enormous growth as patients seek safe, non-dependency-forming therapeutic approaches.

Product Insights

Preference for Extract-based Medical Marijuana Rises as Patients Seek Effective Solutions

By product, the extract form segment is anticipated to hold a medical marijuana market share of 65% in 2025. Products like oils, edibles, and tinctures come under this segment. Studies have found that oils are highly effective in soothing pain. Oils infused with high concentrations of cannabidiol and delta-9-THC are capable of providing more potency compared to edibles like capsules, which are set to propel demand.

The dried flower segment is likely to showcase a considerable CAGR through 2032. Launch of novel products under this segment is projected to forge new prospects. Stada, one of the leading pharmaceutical companies in Germany, for instance, recently entered the medical marijuana industry by introducing two flower products. The company intends to sell three extracts with various CBD and THC compositions in addition to five floral items.

Indication Insights

Surging Use of Medical Marijuana as Pain Treatment Gains Wide Acceptance

In terms of indication, the pain management segment will likely hold a share of 48% in 2025. Medical marijuana has more than 0.3% tetrahydrocannabinol (THC) by weight and contains less cannabidiol (CBD) than hemp. When inhaled or ingested, the CBD or THC tends to bind to certain receptors on the nerve and brain cells, thereby easing discomfort and slowing pain impulses. It also has an anti-inflammatory effect, which helps to reduce pain.  

According to studies, up to 80% of individuals 65 years and older use medical marijuana to cure and manage their pain, and its use has surged eightfold in recent years. A committee formed by the National Academies of Sciences, Engineering, and Medicine analyzed around 10,000 studies associated with marijuana use for medical indications.

For nearly two dozen medical conditions, experts assessed the quality of the available data. Only three health issues, including pain, had substantial or conclusive evidence that cannabis was a useful treatment for them. The other two were nausea and vomiting brought on by chemotherapy and spasms associated with multiple sclerosis.

Medical marijuana is also set to be used for the treatment of seizures, especially in the U.S. President Biden’s Medical Marijuana and Cannabidiol Research Expansion Act clarifies that healthcare professionals may discuss the pros and cons of a marijuana-based treatment with patients suffering from seizures and epilepsy without breaking the Controlled Substances Act.

North America Medical Marijuana Market

Biden Administration’s Federal Review of Cannabis Policy Paving the Way for Potential Reclassification

North America is anticipated to hold a share of 39% in the global market in 2025. Growth is mainly attributed to surging legalization in the U.S. medical marijuana market. To ease the production of marijuana for medical purposes, rules on cannabis are being eased.

• As of February 2024, the U.S. has legalized the use of medical cannabis in 47 states, 3 territories, and the District of Columbia. Despite being illegal at the federal level, federal law's capacity to enforce this is limited by the Rohrabacher–Farr amendment.

President Joe Biden declared in October 2022 that he would request the Attorney General and Secretary of Health and Human Services to begin a review of the federal law's scheduling of cannabis. The Drug Enforcement Administration said in April 2024 that it intended to reclassify cannabis as a Schedule III drug after the FDA reviewed it and Health and Human Services recommended that it be moved to Schedule III.

In Canada, on the other hand, medical marijuana has been a legal treatment option for specific conditions like arthritis since 2001. The federal government of Canada controls the supply of medical marijuana, regulating both production and distribution.

Europe Medical Marijuana Market

U.K., Czech Republic, and Germany to Show Promising Avenues with Decriminalization Efforts

Given that several European Union (EU) nations are working to decriminalize cannabis for personal use, products like marijuana may have a bright future in Europe’s healthcare sector. Sales of cannabis products are predicted to reach over €100 Bn by 2028, with the first therapeutic product being approved for EU-wide marketing in late 2019.

In the U.K., medical marijuana is a prescription-only treatment, and doctors registered with the General Medical Council (GMC) can prescribe such products. The patient must have a diagnosed physical or mental health problem that has not been improved by conventional therapy to be eligible for medical marijuana.

In the Czech Republic, General Practitioners (GPs) will be permitted to prescribe medical marijuana starting on April 1, 2025, to suffering patients. The country's Ministry of Health issued a new decree that led to this policy shift. For chronic, unmanageable pain, the decree permits general practitioners to prescribe medical cannabis.

Since 2017, Germany has allowed the cultivation, import, and sale of cannabis for medical purposes. The cannabis regime was renewed in April 2024 with the Cannabis Act in the country. As per the Act, cannabis is no longer considered to be a narcotic and is not covered by the Narcotics Act. The Law on the Supply of Cannabis for Medical and Medical-Scientific Purposes is a new, independent law that addresses the management of medicinal cannabis, including marijuana, in Germany.

Asia Pacific Medical Marijuana Market

Southeast Asia Moving toward Medical Marijuana Legalization, Creating Investment Opportunities

According to Persistence Market Research, several counties in Southeast Asia may take steps to decriminalize medical marijuana after Thailand legalized it in February 2018. If it turns into reality, investors worldwide are projected to gain significant opportunities in this segment.

When it comes to the legalization and normalization of medical marijuana under government permission, Seoul and Bangkok are anticipated to set the standard in Asia Pacific in the coming years. In November 2018, South Korea became the first country in East Asia to allow medical marijuana. To increase therapy alternatives for individuals with chronic pain, epilepsy, and other diseases, the policy went into effect in March 2019.

A question mark remains in China. Products made from the plant cannabis sativa that contain significant levels of tetrahydrocannabinol (THC) are classified as ‘marijuana’ under the PRC Drugs Prohibition Law, which also forbids their usage in any form. Nonetheless, a few types of cannabis that do not have high THC content can be employed as psychotropic or narcotic medications. It is anticipated to create new opportunities for key players in the forecast period in China.

Leading companies in the global medical marijuana industry are focusing on several strategic initiatives to broaden their presence and gain a competitive advantage. Few of their strategies include partnerships and fast-track approvals. They are also planning to ease the strict laws associated with medical cannabis so that patients can gain access to the product when in need.

Some of the key players are focusing on launching new products to remain at the forefront in local markets. For example, in January 2025, Aurora Cannabis Inc. introduced its brand IndiMed, the first German-cultivated medical cannabis product. The new brand, which is produced at Aurora's top EU-GMP facility in Leuna, Germany, provides the country’s growing patient pool with a supply of premium medical cannabis that is farmed and sold domestically.

Key Industry Developments

• In February 2025, Aurora Cannabis Inc., based in Canada, joined hands with MedReleaf Australia to eliminate the need for concession cards for patients to gain access to medical cannabis products under the IndiMed brand. Any patient in Australia can now be prescribed IndiMed products due to the removal of this qualifying requirement, increasing patient access to premium medicinal cannabis options.
• In February 2025, some adults would be able to grow marijuana at home under a new bill that was submitted to the Florida Senate. After voters rejected an amendment to legalize marijuana for adults 21 and older, lawmakers are now working to increase access to the drug in Florida. Medical marijuana users would be permitted to cultivate up to two cannabis plants at home under Senate Bill 546, provided they apply for and receive a ‘cultivation certificate’ from the Department of Agriculture and Consumer Services.
• In January 2025, in Nebraska, three legislative proposals were introduced by State Sens. Danielle Conrad of Lincoln, Ben Hansen of Blair and Terrell McKinney of Omaha to stipulate the regulatory and licensing duties of the Nebraska Medical Cannabis Commission. All three proposals would enable Nebraskans to apply for a registry card, which would identify them as a qualified patient, following a formal recommendation for medical cannabis from a medical professional.